Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient Visit in ACCELERATE Expecting Jul. '16

Eli Lilly and Company LLY has accepted the recommendation of the ACCELERATE study data monitoring committee to continue the Phase 3 trial of the investigational medicine evacetrapib, based on data from an interim futility analysis. Last patient visit in ACCELERATE – which is evaluating evacetrapib in approximately 12,000 patients with high-risk atherosclerotic cardiovascular disease (ASCVD) – is expected in July 2016. "We believe that evacetrapib, if approved, could offer a significant benefit in the treatment of high-risk cardiovascular disease," said David Ricks, Lilly senior vice president and president of Lilly Bio-Medicines. "While pleased that the trial continues, we need to complete the ACCELERATE study to understand the potential for evacetrapib. The interim futility test was designed to assess whether the drug had any possibility of achieving its primary endpoints. We look forward to receiving the ACCELERATE results in 2016."